Your browser doesn't support javascript.
loading
What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?
McCulloch, Rory; Eyre, Toby A; Rule, Simon.
Afiliação
  • McCulloch R; Department of Haematology, Peninsula Medical School, University of Plymouth, Plymouth, UK.
  • Eyre TA; Department of Haematology, Oxford University Hospitals, Oxford, UK.
  • Rule S; Department of Haematology, Peninsula Medical School, University of Plymouth, John Bull Building, Plymouth PL6 8BU, UK. Electronic address: simon.rule@plymouth.ac.uk.
Hematol Oncol Clin North Am ; 34(5): 923-939, 2020 10.
Article em En | MEDLINE | ID: mdl-32861287
ABSTRACT
In this review, we explore insights into the pathophysiology of Bruton tyrosine kinase inhibitor (BTKi) resistance in mantle cell lymphoma, and consider potential therapeutic targets. We review the possible clinical benefits of giving BTKis alongside other novel therapies, and evaluate clinical data for treatment strategies post BTKi progression that may help guide current practice. We conclude by considering future approaches, including the potential role of chimeric antigen receptor T-cell therapy.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoterapia Adotiva / Resistencia a Medicamentos Antineoplásicos / Linfoma de Célula do Manto / Inibidores de Proteínas Quinases / Tirosina Quinase da Agamaglobulinemia Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoterapia Adotiva / Resistencia a Medicamentos Antineoplásicos / Linfoma de Célula do Manto / Inibidores de Proteínas Quinases / Tirosina Quinase da Agamaglobulinemia Idioma: En Ano de publicação: 2020 Tipo de documento: Article